Collectively, these observations demonstrate that first-line neoadjuvant neratinib therapy potently inhibits orthotopic HER2+ve tumour growth and dramatically reduces the incidence of metastases in the brain and other organs in immune-competent BALB/C mice, resulting in a significant improvement in disease-free survival. Here, ERBB2 is linked to neoplasm.